Blog
Dihexa: cell-differentiation research and a retracted cognition paper
A cell-culture protocol uses Dihexa during liver-cell differentiation. A separate, often-cited cognition paper was retracted and must not support benefit claims.
Evidence discussed: In-vitro research protocol, not a human cognition trial.
What the researchers studied
A 2016 protocol describes producing liver-like cells from human pluripotent stem cells using small molecules. Dihexa appears alongside other agents during one stage of differentiation. This is a laboratory application, not evidence that taking Dihexa improves memory. [1]
How to interpret the result
A multicomponent cell-culture protocol cannot isolate every effect of Dihexa or establish clinical efficacy. Human-derived cells are not the same as a study in human participants. This work did not test long-term exposure or treatment of dementia.
Why source status matters
A separate 2014 paper frequently cited for Dihexa cognition claims is listed by PubMed as retracted, with a 2025 retraction notice. Its reported benefits should not be treated as reliable supporting evidence. [2]
This original editorial summary provides no diagnosis, dosing or treatment advice. Neither paper tests or certifies a PeptiKing product.
Sources
[1] Small-molecule-directed hepatocyte-like cell differentiation (2016). PMID: 27532814. Summary based on the indexed abstract.
[2] Retraction notice for the 2014 Dihexa cognition paper (2025). PMID: 40312093. Used only to document retraction, not to support an efficacy claim.